- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01438125
MF-4181 for the Reduction of Scars Secondary to Abdominoplasty or Laparoscopy/Laparotomy Gynecologic Procedures
March 28, 2013 updated by: Halscion, Inc.
A Pilot Study to Evaluate the Safety and Preliminary Efficacy of MF-4181 for the Reduction of Scars Secondary to Abdominoplasty or Laparoscopy/Laparotomy Gynecologic Procedures
The objective of the study is to evaluate the safety and preliminary efficacy of MF-4181, a hydrogel scaffold, in improving scars and their resulting consequences following abdominoplasty or laparoscopy/laparotomy gynecologic procedures.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
100
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Lublin, Poland
- II Katedra i Klinika Ginekologii Onkologicznej i Ginekologii
-
Lublin, Poland
- Klinika Ginekologii Operacyjnej
-
Warsaw, Poland
- Klinika Ginekologii i Ginekologii Onkologicznej
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 60 years (Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Male or female subjects between 18 and 60 years of age undergoing abdominoplasty without intraoperative flexion at time of skin excision OR female subjects between 18 and 60 years of age undergoing diagnostic and/or operative laparoscopy/laparotomy gynecologic procedures.
- Weight between 50 and 95 kg with BMI between 20 and 30
- Able and willing to give written informed consent
- Willing to comply with the follow-up schedule
Exclusion Criteria:
- Need of concomitant surgical procedures that would be performed at the same time as the index surgical procedure or that would influence the healing process
- Previous abdominal surgery with scars or adhesions that would limit or complicate the index surgical procedure
- Presence of ventral or umbilical hernia requiring the use of prosthetic material
- Heart disease
- Pregnant or planning to become pregnant during the course of the study; the exception to this exclusion is if ectopic pregnancy is the reason for the procedure
- History of coagulopathy or bleeding disorder
- An American Society of Anesthesiologists (ASA) Score of >II
- Known diabetes
- Current or history of heavy smoking (i.e., 10 pack years)
- Active skin disorder or other condition that may interfere with healing or history of such a condition
- Planned use of an ON-Q® pain control device (I-Flow Corporation, Lake Forest, CA) or similar incisional intervention post index procedure
- Active collagen vascular disease or vasculitis, e.g., systemic lupus erythematosus, polyarteritis, dermatomyositis, systemic scleroderma or thrombotic thrombocytopenic purpura
- Anticipated use of DERMABOND® or another topical skin adhesive type of wound closure
- Unwilling or unable to return for follow-up visits
- Regular, continuous use of systemic corticosteroid therapy or topical corticosteroid use in the area to be treated
- Current participation or participation within the last 3 months in the study of an investigational drug, device, or biologic
- Unable or unwilling to follow post-operative instructions
- Known hypersensitivity to MF-4181, dextran, or any of its constituent materials
- Previous participation in this study to avoid multiple enrollments of an individual subject.
- Chemotherapy or hormone therapy for cancer within the last 3 months, or probability that these treatments will be required during the 6 months of study participation.
- Current or past radiation therapy in the abdominal incision
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: MF-4181
Scar halves randomized to treatment with device, opposite side treated per standard of care
|
Surgical procedure will be performed as per the standard of care.
Scar halves randomized to treatment with device (MF-4181), opposite side treated per standard of care.
Other Names:
|
Active Comparator: Standard surgical wound closure
|
Surgical procedure will be performed as per the standard of care.
Scar halves randomized to treatment with device (MF-4181), opposite side treated per standard of care.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Safety, defined as the absence of device related serious adverse events at 3 months post last MF-4181 treatment
Time Frame: 3 Months
|
3 Months
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Investigator and Subject Observer Scar Assessment Scale (POSAS)
Time Frame: 12 months
|
12 months
|
Investigator and Subject Anchored Visual Analog Scar Evaluation Scale
Time Frame: 12 Months
|
12 Months
|
Digital photographs evaluated by independent medical experts
Time Frame: 12 Months
|
12 Months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Wlodzimierz Baranowski, MD, Unaffliated
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
February 1, 2009
Primary Completion (Actual)
May 1, 2011
Study Completion (Actual)
May 1, 2011
Study Registration Dates
First Submitted
September 20, 2011
First Submitted That Met QC Criteria
September 20, 2011
First Posted (Estimate)
September 21, 2011
Study Record Updates
Last Update Posted (Estimate)
March 29, 2013
Last Update Submitted That Met QC Criteria
March 28, 2013
Last Verified
March 1, 2013
More Information
Terms related to this study
Other Study ID Numbers
- HAL-0082
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Scars
-
IBSA Farmaceutici Italia SrlDerming SRLRecruitingAcne Scars - Mixed Atrophic and Hypertrophic | Ice Pick Scars | Rolling Scars | Boxcar ScarsItaly
-
Cynosure, Inc.Terminated
-
Innovative MedicalCompleted
-
Cynosure, Inc.Completed
-
Northwestern UniversityTerminated
-
University Hospital, GhentCompleted
-
Organ, Tissue, Regeneration, Repair and ReplacementRecruiting
-
Cynosure, Inc.Completed
-
Region SkaneCompleted
-
University Hospital, GhentCompleted
Clinical Trials on MF-4181
-
Halscion, Inc.Completed
-
Bausch & Lomb IncorporatedCompleted
-
Purdue UniversityNot yet recruiting
-
Purdue UniversityUniversity of OregonNot yet recruiting
-
Coopervision, Inc.Completed
-
Alcon ResearchCompleted
-
Campus Bio-Medico UniversityUniversity of Rome Tor Vergata; University Hospital of Ferrara; Arcispedale Santa... and other collaboratorsTerminatedIschemic Stroke | Stroke, AcuteItaly
-
VA Office of Research and DevelopmentNot yet recruitingDepression | Anxiety | Post Traumatic Stress Disorder (PTSD)United States
-
Campus Bio-Medico UniversityUnknown
-
Innovative MedicalCompletedCataractUnited States